$19.50 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest



Aura Biosciences, Inc. is a clinical-stage biotechnology company. The Company operates a platform, which focuses on ocular and urologic oncology. Its platform enables targeting of a range of solid tumors using Virus-Like Particles (VLPs) that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates (VDCs). The Company's VDC platform offers a range of portfolio of targeted oncology therapeutics. It engaged in developing AU-011 for the treatment of early-stage disease, which includes small melanomas and indeterminate lesions. Its product candidate, AU-011 consists of a human papilloma virus (HPV)-derived VLP conjugated to thousands of infrared laser-activated molecules. VDC prevents the conjugation from interfering with tumor binding enabling its selectivity to specifically modified HSPGs on tumor cells but not to normal cells. In addition, the Company is developing AU-011 for the treatment of non-muscle invasive bladder cancer (NMIBC).

Stock Analysis

last close $16.26
1-mo return 0.9%
3-mo return -
avg daily vol. 24.56T
52-week high 26.16
52-week low 13.5
market cap. $479M
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. -
inst own. 30.8%

Subscribe now for daily local and international financial news